Microbix' CEO Statement on Universal Vaccine

About this update from Microbix Biosystems Inc.

[{"type":"text","content":"\n\n\n\n Feb. 8, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nTORONTO, Feb. 8 /CNW/ - Microbix Biosystems Inc. (TSX: MBX), a\n biotechnology company commercializing novel biological technologies for\n human healthcare, which has the financing and senior management in\n place to build and operate the largest vaccine production facility in\n China and the third largest in the world, responded today to a media\n report that has fueled unfounded speculation that a universal influenza\n vaccine is a near-term possibility. Microbix CEO, William J. Gastle,\n made the following statements:  \n\n\nCommenting on the universal vaccine:\n\n\n"According to the CDC, FDA and NIH experts who spoke on this subject at\n the World Vaccine Congress Meeting which we attended in November\n 2010 in Washington D.C., any universal vaccine, however effective, will\n likely require annual boosts with seasonal products. The idea is that\n the universal vaccine is to provide a base-line protection, but the\n strength of that protection will vary with each new strain that\n emerges. According to these experts there will always be a demand for\n egg-based seasonal vaccine. We have seen the data. There is a lot of\n variation between target populations which may likely mean the\n development of a universal flu vaccine will, in the end, be an academic\n exercise. Lead time for these sorts of products has historically been significant.\n For example, despite the fact that recomb...

More updates from Microbix Biosystems Inc.